Developer docs
API playgroundTry for free, no card

Search company profiles

Algorithme Pharma

Full company profile

uuid000ll32

Namestring
Algorithme Pharma
Legal namestring
Altasciences
Websiteurl
algopharm.com
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization headquartered in Laval, Canada, with clinical operations now spanning Canada and the United States (including a Los Angeles Phase I-II clinic). Founded in 1992, the company employs 501-1,000 staff and positions itself as a single-vendor partner for biopharmaceutical sponsors of all sizes, covering preclinical safety testing (GLP and non-GLP), clinical pharmacology from first-in-human through end of Phase II, bioanalytical services from preclinical through Phase IV, formulation development, Phase I-through-commercial manufacturing, and ICH stability testing.

The core technology offering is the proprietary "Acceleration Platform," an integrated preclinical-to-proof-of-concept workflow complemented by a "Tell Us Once" sponsor data management program and a "Proactive Drug Development" methodology. The platform's marketed claim is a reduction in program duration of up to 40 percent, anchored in part on a published case study advancing an incretin-based therapy from safety assessment to proof-of-concept in approximately 22 months. Operations are supported by GLP-compliant facilities and ICH stability testing capabilities, enabling submission-ready documentation.

The business model is fee-for-service professional services revenue, with study or program pricing negotiated on a project-by-project basis (no public pricing). Go-to-market is enterprise sales-led, with dedicated business development and account management teams engaging biopharma decision-makers directly across North America. Marketing is content-driven and built around the "Altascientist" scientific journal (now distributed as an audiobook), webinars, video, industry events, and a 30,000+ VIP subscriber base. Customers span enterprise pharmaceutical companies (Idenix, a wholly-owned Merck subsidiary; Ionis Pharmaceuticals), mid-market biotechs (NeuroTrauma Sciences, Locemia Solutions), and emerging sponsors (gIcare Pharma), with therapeutic scope spanning standard small-molecule and biologic studies, biosimilars, and specialized assessments such as human abuse potential, QT, and renal/hepatic impairment.

Short descriptiontext

Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization providing preclinical safety testing, Phase I-II clinical pharmacology, bioanalysis, and manufacturing services to biopharmaceutical companies of all sizes across North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLaval, Canada
HQ citystring
Laval
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, clinical pharmacology trials, preclinical safety testing, bioanalytical laboratory services, drug development outsourcing
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) / Early Phase Drug Development Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Preclinical Services
TypeProfessional Services
Description

Fee-for-service preclinical safety assessments for small and large molecules including GLP toxicology, safety pharmacology, pharmacokinetics, and immunotoxicology studies. Revenue is project-based with studies scoped individually for each sponsor.

altasciences.com
2Clinical Services
TypeProfessional Services
Description

Clinical pharmacology trials from first-in-human through end of Phase II, including proof-of-concept studies, bioavailability/bioequivalence, and specialized populations. Revenue generated through per-study contracts with pharmaceutical and biotech sponsors.

altasciences.com
3Manufacturing and Analytical Services
TypeProfessional Services
Description

Formulation development, Phase I through commercial manufacturing, and ICH stability testing. Revenue from contract manufacturing and analytical testing services.

altasciences.com
4Bioanalysis Services
TypeProfessional Services
Description

Bioanalytical laboratory services supporting preclinical through Phase IV studies, available as standalone or integrated package. Revenue from analytical testing contracts.

altasciences.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1The Altascientist
Description

Scientific journal published by the company

altasciences.com
Core offering1 text field

Algorithme Pharma, operating as Altasciences, is a mid-size early phase contract research organization (CRO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology trials from first-in-human through end of Phase II, bioanalytical laboratory services, and manufacturing and analytical services. The company provides integrated drug development support from lead candidate selection to proof of concept, operating facilities in Canada and the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduce program durations by up to 40%
+1 more record
Product and service1 record
1Preclinical Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Celerion is a closely comparable early-phase clinical pharmacology CRO offering first-in-human through Phase II services, bioanalysis, and specialized PK studies — directly overlapping Altasciences' core clinical pharmacology footprint.

TypeBroad incumbent
Description

Charles River is a global CRO/CDMO with a dominant preclinical and early-phase clinical presence, including safety assessment, bioanalysis, and Phase I capabilities that overlap Altasciences' preclinical services and bioanalysis offerings.

TypeDirect peer
Description

Worldwide Clinical Trials focuses on early-stage clinical development and bioanalytical services for biopharma, positioning it as a direct peer in the Phase I–II clinical pharmacology and bioanalysis segments.

TypeBroad incumbent
Description

Parexel is a Tier 1 global CRO offering early-phase clinical, bioanalysis, and regulatory services to biopharma, representing a broader incumbent alternative for sponsors evaluating Altasciences.

TypeBroad incumbent
Description

IQVIA is the largest global CRO with Phase I clinical, bioanalytical, and R&D consulting capabilities across the entire development continuum, competing with Altasciences on enterprise biopharma RFPs.

TypeBroad incumbent
Description

Labcorp/Covance operates central laboratories, bioanalytical services, and early-phase clinical operations globally, overlapping with Altasciences on bioanalysis and early clinical trial testing.

TypeEmerging player
Description

Frontage provides bioanalytical, CMC, and early clinical development services to biopharma — an adjacent specialty CRO whose bioanalysis work directly competes with Altasciences' Bioanalysis Services.

TypeBroad incumbent
Description

SGS operates a global clinical and bioanalytical CRO business with early-phase and central laboratory services that compete for biopharma early-development outsourcing work.

TypeBroad incumbent
Description

Eurofins' BioPharma Product Testing and discovery services include bioanalytical and preclinical capabilities that overlap with Altasciences' bioanalysis and research support offerings.

TypeBroad incumbent
Description

Medpace is a mid-to-large full-service CRO with growing early-phase and bioanalytical capabilities, representing a competitive alternative for biotech sponsors evaluating Altasciences for early development work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Algorithme Pharma

Contract Research Organization (CRO) / Early Phase Drug Development Servicesalgopharm.com

Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization providing preclinical safety testing, Phase I-II clinical pharmacology, bioanalysis, and manufacturing services to biopharmaceutical companies of all sizes across North America.

What Algorithme Pharma does

Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization headquartered in Laval, Canada, with clinical operations now spanning Canada and the United States (including a Los Angeles Phase I-II clinic). Founded in 1992, the company employs 501-1,000 staff and positions itself as a single-vendor partner for biopharmaceutical sponsors of all sizes, covering preclinical safety testing (GLP and non-GLP), clinical pharmacology from first-in-human through end of Phase II, bioanalytical services from preclinical through Phase IV, formulation development, Phase I-through-commercial manufacturing, and ICH stability testing.

The core technology offering is the proprietary "Acceleration Platform," an integrated preclinical-to-proof-of-concept workflow complemented by a "Tell Us Once" sponsor data management program and a "Proactive Drug Development" methodology. The platform's marketed claim is a reduction in program duration of up to 40 percent, anchored in part on a published case study advancing an incretin-based therapy from safety assessment to proof-of-concept in approximately 22 months. Operations are supported by GLP-compliant facilities and ICH stability testing capabilities, enabling submission-ready documentation.

The business model is fee-for-service professional services revenue, with study or program pricing negotiated on a project-by-project basis (no public pricing). Go-to-market is enterprise sales-led, with dedicated business development and account management teams engaging biopharma decision-makers directly across North America. Marketing is content-driven and built around the "Altascientist" scientific journal (now distributed as an audiobook), webinars, video, industry events, and a 30,000+ VIP subscriber base. Customers span enterprise pharmaceutical companies (Idenix, a wholly-owned Merck subsidiary; Ionis Pharmaceuticals), mid-market biotechs (NeuroTrauma Sciences, Locemia Solutions), and emerging sponsors (gIcare Pharma), with therapeutic scope spanning standard small-molecule and biologic studies, biosimilars, and specialized assessments such as human abuse potential, QT, and renal/hepatic impairment.

Algorithme Pharma firmographics

Firmographics
Name
Algorithme Pharma
Legal name
Altasciences
Website
https://algopharm.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Algorithme Pharma, doing business as Altasciences, is a mid-size early-phase contract research organization providing preclinical safety testing, Phase I-II clinical pharmacology, bioanalysis, and manufacturing services to biopharmaceutical companies of all sizes across North America.
Ownership category
akta.pro rank

Algorithme Pharma industry classification

Industry
Product category
Contract Research Organization (CRO) / Early Phase Drug Development Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Contract research organization
  • Clinical pharmacology trials
  • Preclinical safety testing
  • Bioanalytical laboratory services
  • Drug development outsourcing

Where Algorithme Pharma is headquartered

Location

Headquarters

HQ city
Laval
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

Algorithme Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Preclinical Services: Fee-for-service preclinical safety assessments for small and large molecules including GLP toxicology, safety pharmacology, pharmacokinetics, and immunotoxicology studies. Revenue is project-based with studies scoped individually for each sponsor.
  2. Clinical Services: Clinical pharmacology trials from first-in-human through end of Phase II, including proof-of-concept studies, bioavailability/bioequivalence, and specialized populations. Revenue generated through per-study contracts with pharmaceutical and biotech sponsors.
  3. Manufacturing and Analytical Services: Formulation development, Phase I through commercial manufacturing, and ICH stability testing. Revenue from contract manufacturing and analytical testing services.
  4. Bioanalysis Services: Bioanalytical laboratory services supporting preclinical through Phase IV studies, available as standalone or integrated package. Revenue from analytical testing contracts.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Algorithme Pharma product offering

Product offering

Core offering

Algorithme Pharma, operating as Altasciences, is a mid-size early phase contract research organization (CRO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology trials from first-in-human through end of Phase II, bioanalytical laboratory services, and manufacturing and analytical services. The company provides integrated drug development support from lead candidate selection to proof of concept, operating facilities in Canada and the United States.

Differentiator

Problem solved

Functional benefit

Brands

  • The Altascientist: Scientific journal published by the company

Products and services

  • Preclinical Services

Quantifiable outcome

  • Reduce program durations by up to 40%
  • +1 more outcomes

Companies that use Algorithme Pharma

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Algorithme Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Algorithme Pharma partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Algorithme Pharma competitors and assessment

Company assessment

Direct peers

  • Celerion: Celerion is a closely comparable early-phase clinical pharmacology CRO offering first-in-human through Phase II services, bioanalysis, and specialized PK studies — directly overlapping Altasciences' core clinical pharmacology footprint.
  • Worldwide Clinical Trials: Worldwide Clinical Trials focuses on early-stage clinical development and bioanalytical services for biopharma, positioning it as a direct peer in the Phase I–II clinical pharmacology and bioanalysis segments.

Broad incumbents

  • Charles River Laboratories: Charles River is a global CRO/CDMO with a dominant preclinical and early-phase clinical presence, including safety assessment, bioanalysis, and Phase I capabilities that overlap Altasciences' preclinical services and bioanalysis offerings.
  • Parexel International: Parexel is a Tier 1 global CRO offering early-phase clinical, bioanalysis, and regulatory services to biopharma, representing a broader incumbent alternative for sponsors evaluating Altasciences.
  • IQVIA: IQVIA is the largest global CRO with Phase I clinical, bioanalytical, and R&D consulting capabilities across the entire development continuum, competing with Altasciences on enterprise biopharma RFPs.
  • Labcorp Drug Development (Covance): Labcorp/Covance operates central laboratories, bioanalytical services, and early-phase clinical operations globally, overlapping with Altasciences on bioanalysis and early clinical trial testing.
  • SGS Life Sciences (SGS Santé): SGS operates a global clinical and bioanalytical CRO business with early-phase and central laboratory services that compete for biopharma early-development outsourcing work.
  • Eurofins Discovery / Bioanalytical Services: Eurofins' BioPharma Product Testing and discovery services include bioanalytical and preclinical capabilities that overlap with Altasciences' bioanalysis and research support offerings.
  • Medpace: Medpace is a mid-to-large full-service CRO with growing early-phase and bioanalytical capabilities, representing a competitive alternative for biotech sponsors evaluating Altasciences for early development work.

Emerging players

  • Frontage Laboratories: Frontage provides bioanalytical, CMC, and early clinical development services to biopharma — an adjacent specialty CRO whose bioanalysis work directly competes with Altasciences' Bioanalysis Services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Algorithme Pharma social profiles

Digital presence

Algorithme Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Algorithme Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Algorithme Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Algorithme Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Algorithme Pharma

What does Algorithme Pharma do?

Algorithme Pharma, operating as Altasciences, is a mid-size early phase contract research organization (CRO) offering biopharmaceutical companies preclinical safety testing, clinical pharmacology trials from first-in-human through end of Phase II, bioanalytical laboratory services, and manufacturing and analytical services. The company provides integrated drug development support from lead candidate selection to proof of concept, operating facilities in Canada and the United States.

Is Algorithme Pharma a public or private company?

Algorithme Pharma is a private company. It is classified as unknown and is currently operating.

When was Algorithme Pharma founded?

Algorithme Pharma was founded in 1995. It employs 1,001 to 5,000 people.

Where is Algorithme Pharma based?

Algorithme Pharma is headquartered in Laval, Canada, in the North America region.

How does Algorithme Pharma make money?

Four revenue lines are on record. Preclinical Services are the primary driver. The others are clinical Services, manufacturing and Analytical Services and bioanalysis Services.

Who are Algorithme Pharma's main competitors?

Direct peers on record are Celerion and Worldwide Clinical Trials. Broad incumbents are Charles River Laboratories, Parexel International, IQVIA, Labcorp Drug Development (Covance), SGS Life Sciences (SGS Santé), Eurofins Discovery / Bioanalytical Services and Medpace. Frontage Laboratories is listed as an emerging player.

Does Algorithme Pharma have an API?

No public API is recorded for Algorithme Pharma.

What industry is Algorithme Pharma in?

Algorithme Pharma's product category is Contract Research Organization (CRO) / Early Phase Drug Development Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals